EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-Inflammatory and Survival Benefits of Dipeptidyl Peptidase 4 Inhibitors Among Patients with Gout, T2DM Patients and Chronic Kidney Disease

Shachaf Shiber iD, Amir Sharabi, Irit Ayalon, Eviatar Naamany, Alon Grossman, Yair Molad

Experimental and Clinical Endocrinology & Diabetes · 01.05.2025 · 133 (05) · 253-258

DOI: 10.1055/a-2565-7419 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.05.2025. Verfasst von Shachaf Shiber und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology, Rabin Medical Center, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2, Gout. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gout and type 2 diabetes mellitus (T2DM) often coexist and are associated with chronic kidney disease (CKD) and increased mortality. Dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly used in T2DM, may offer additional benefits, such as reducing inflammation and uric acid levels. This study aimed to assess the impact of DPP-4 inhibitors on gout flare frequency, serum uric acid (sUA) levels, and survival in patients with gout, T2DM, and CKD. A cross-sectional, retrospective, longitudinal study was conducted over 6 years between 2016 – 2022, including patients with gout and T2DM from the largest healthcare provider in Israel. Patients were divided into treatment and control groups based on DPP4-inhibitor status treatment. The primary outcome was the number of gout arthritis attacks over 1 year, reflected by the number of emergency room visits. Secondary outcomes included mean serum high-sensitive C-reactive protein (hs-CRP) levels and survival rates over the study period. DPP-4 inhibitor treatment significantly reduced sUA levels (5.2±1.3 mg/dL vs. 5.9±2.2 mg/dL, p=0.05) and hs-CRP levels (0.50±0.19 mg/dL, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dipeptidyl-Peptidase IV InhibitorsRenal Insufficiency, ChronicDiabetes Mellitus, Type 2GoutAnti-Inflammatory AgentsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesLongitudinal StudiesCross-Sectional StudiesSurvival RateUric Acid

Substanzen

Dipeptidyl-Peptidase IV InhibitorsAnti-Inflammatory AgentsUric Acid

Autor:innen und Institutionen

  • Rheumatology, Rabin Medical Center, Petah Tikva, Israel.
  • Tel Aviv University Faculty of Medicine, Tel Aviv, Israel.

ORCID-Profile: Shachaf Shiber

Zitieren

APA

Shiber, S., Sharabi, A., Ayalon, I., Naamany, E., Grossman, A., & Molad, Y. (2025). Anti-Inflammatory and Survival Benefits of Dipeptidyl Peptidase 4 Inhibitors Among Patients with Gout, T2DM Patients and Chronic Kidney Disease. Experimental and Clinical Endocrinology & Diabetes, 133(05), 253-258. https://doi.org/10.1055/a-2565-7419

Vancouver

Shiber S, Sharabi A, Ayalon I, Naamany E, Grossman A, Molad Y. Anti-Inflammatory and Survival Benefits of Dipeptidyl Peptidase 4 Inhibitors Among Patients with Gout, T2DM Patients and Chronic Kidney Disease. Experimental and Clinical Endocrinology & Diabetes. 2025;133(05):253-258. doi:10.1055/a-2565-7419

BibTeX
@article{Shiber2025,
  author = {Shiber, Shachaf and Sharabi, Amir and Ayalon, Irit and Naamany, Eviatar and Grossman, Alon and Molad, Yair},
  title = {Anti-Inflammatory and Survival Benefits of Dipeptidyl Peptidase 4 Inhibitors Among Patients with Gout, T2DM Patients and Chronic Kidney Disease},
  journal = {Experimental and Clinical Endocrinology & Diabetes},
  year = {2025},
  volume = {133},
  number = {05},
  pages = {253--258},
  doi = {10.1055/a-2565-7419}
}
Kostenlos starten →